Both sickle cell therapies NICE has recommended reached patients through managed access, and one lost its licence when the confirmatory data did not hold.
The defining UK sickle cell precedent is a withdrawal, not a rejection. NICE recommended crizanlizumab in October 2021 under technology appraisal TA743, as an option for preventing recurrent vaso-occlusive crises in people aged 16 and over, but only if the conditions of a managed access agreement were met. That agreement existed because the evidence carried real uncertainty and NICE wanted more data before committing to routine commissioning. The data arrived and did not hold. The STAND confirmatory trial failed to show a reduction in crises leading to a healthcare visit, the European Commission revoked the conditional marketing authorisation in August 2023, the MHRA withdrew the UK licence, and NICE withdrew TA743. A drug that had already cleared NICE lost the market on efficacy.
That reframes the pricing question for any new UK sickle cell agent. The constraint is not a published cost-per-QALY ceiling to price beneath. It is that NICE will grant access on uncertain evidence and reclaim it, so the price and the confirmatory evidence plan have to be built as a single decision. Casgevy followed the same conditional route, recommended under TA1044 within a managed access agreement rather than straight to routine commissioning. Our model therefore prices the asset across both managed-access and routine-commissioning scenarios, and weights the revenue case by confirmatory-trial risk instead of assuming one approved price holds for the life of the asset.
Every sickle cell therapy NICE has recommended reached patients conditionally, and the conditions have already reclaimed one.
| Agent | NICE Outcome | Access Route | What Happened Next |
|---|---|---|---|
| Crizanlizumab (Adakveo, Novartis) | TA743 recommended, October 2021, ages 16 and over | Managed access agreement, conditional on further data collection | Licence revoked 2023 after STAND failed its primary endpoint; NICE withdrew the guidance |
| Casgevy (exagamglogene autotemcel, Vertex) | TA1044 recommended | Managed access agreement; £1.65M list, confidential NHS discount | In managed access, with long-term data collection ongoing |
| Novel non-gene agent | Target: routine commissioning rather than a conditional route | Priced and evidenced to avoid managed access where possible | Modelled across both routes, with confirmatory-trial risk weighted into the revenue case |
Sources: NICE technology appraisal TA743, crizanlizumab, published October 2021 and subsequently withdrawn following revocation of the marketing authorisation; NICE technology appraisal TA1044, Casgevy, recommended within a managed access agreement; European Medicines Agency and European Commission decisions revoking the Adakveo conditional marketing authorisation, 2023, including the STAND confirmatory-trial result.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The TA743 managed access conditions, the STAND result that triggered revocation, and the confirmatory-trial risk weighting to build into the revenue model
Delivers
- The two routes NICE has used in UK sickle cell, the evidence commitments each carries, and the price implications of accepting a conditional route
Delivers
- The model's target WAC range, per-patient NHS hospitalisation-offset modelling, and the GTN waterfall and PAS negotiation layers specific to the UK sickle cell market
Custom model delivered in 72 hours.
Assess this reportWhat's inside
- Why confirmatory-evidence risk, not a cost-per-QALY ceiling, governs UK sickle cell pricing
- What crizanlizumab's withdrawal changed for every agent that follows it
- The two routes NICE has actually used in sickle cell and what each one demands
- Where a novel non-gene agent should aim on that ladder
- How a one-time gene therapy price is absorbed against ongoing NHS management cost
- Where amortisation and outcome-based structures apply in sickle cell
- TA743's managed access conditions and the evidence uncertainty they were built to resolve
- How the STAND result moved from a trial failure to a revoked licence
- The WAC range the model produces once NHS hospitalisation offsets are built into the case
- Positioning against hydroxycarbamide's generic cost floor
- The WAC-to-net waterfall decomposed by NHS commissioning route
- Where a confidential PAS discount does and does not change the NICE outcome
- Sequencing recommendation across NHS England specialist centres
- Conservative, base, and aggressive revenue scenarios tied to NICE submission timing
- The open pricing questions your team must close before the UK launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary NICE and NHS sources and live commissioning documentation, not secondary summaries. Findings are independently verified before inclusion.
Sickle cell disease UK pricing sources: NICE TA743 (crizanlizumab, recommended 2021 and later withdrawn), NICE TA1044 (Casgevy), and the European Medicines Agency and European Commission decisions revoking the Adakveo conditional marketing authorisation in 2023.
- TA743's original recommendation, its managed access conditions, and NICE's subsequent withdrawal verified against the live NICE guidance record, not inferred from the drug's current absence from the UK market
- Crizanlizumab's licence revocation verified against the European Medicines Agency and European Commission decisions of 2023, including the STAND confirmatory-trial result that triggered them
- Casgevy's list price and managed access route verified against NICE TA1044
Frequently asked questions
Commission this model
AXLRx delivers sickle cell disease pricing strategy models built for market access and pricing teams weighing a managed access route against routine commissioning under NICE. Custom model in 72 hours.
Specify your indication, target WAC range, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and NICE threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.